Stifel Nicolaus analyst Derek Archila maintained a Hold rating on Aimmune Therapeutics (AIMT) today and set a price target of $34.50. The company’s shares closed last Friday at $12.60, close to its 52-week low of $10.09.
According to TipRanks.com, Archila is a 4-star analyst with an average return of 9.7% and a 45.8% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Phasebio Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aimmune Therapeutics with a $37.61 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $37.00 and a one-year low of $10.09. Currently, Aimmune Therapeutics has an average volume of 1.09M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.
